Government of Saskatchewan ministries, Crown corporations and organizations are implementing contingency plans to minimize the impacts of postal service disruption.
Les ministères, sociétés d’État et organismes du gouvernement de la Saskatchewan mettent en œuvre des plans d’urgence (en anglais) visant à réduire les répercussions de l’interruption du service des postes.
Google Translate Disclaimer
A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:
Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.
Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).
Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.
Released on January 30, 2024
More children in Saskatchewan living with cystic fibrosis (CF) are now eligible for Trikafta, a medication that improves lung function. Starting February 1, 2024, coverage of Trikafta will be available to CF patients two to five years of age who meet the medical criteria.
“We are pleased to expand coverage for this treatment for more Saskatchewan children with cystic fibrosis,” Health Minister Everett Hindley said. “Trikafta has been shown to improve quality of life in patients living with CF, so this expanded coverage means more children with CF can benefit and lead healthier lives.”
Although there is no cure for CF, Trikafta works to correct the underlying cause of CF.
In December 2023, the Canadian Agency for Drugs and Technologies in Health issued a recommendation that jurisdictions expand coverage of Trikafta for patients two to five years who meet certain medical criteria. Successful pricing negotiations have recently been completed through the pan-Canadian Pharmaceutical Alliance.
“Saskatchewan was one of the first provinces to fund Trikafta for both the six years and older and 12 years and older age groups, and today has continued to recognize the treatment's transformative value by expanding coverage to include children ages two to five years old,” Cystic Fibrosis Canada President and CEO Kelly Grover said. “While not a cure, starting young children with cystic fibrosis on modulator therapy as early as possible could protect their health and prevent significant structural lung damage from occurring - we celebrate this news alongside our CF community in Saskatchewan, who has worked tirelessly for this day.”
In Saskatchewan, coverage of Trikafta for CF patients ages six to 12 came into effect in 2022, while coverage for patients ages 12 and older began in 2021. Approximately 90 people in Saskatchewan already benefit from Trikafta coverage. An estimated five more children are expected to become eligible in the first year with the expanded criteria to include ages two to five.
Patients with CF or parents/guardians of children with CF who think they may benefit from therapy with Trikafta are encouraged to speak with their physician.
Coverage is also available in Saskatchewan for two other CF medications which target specific genetic mutations of the disease: Orkambi and Kalydeco. Coverage of Orkambi was expanded in July 2021 for patients two years of age and older who meet certain medical criteria. Kalydeco has been listed on the Saskatchewan Formulary since 2014.
According to the Canadian Cystic Fibrosis Registry, there are more than 4,300 CF patients in Canada and approximately 125 patients in Saskatchewan.
-30-
For more information, contact:
MediaWe need your feedback to improve saskatchewan.ca. Help us improve
